fosamax plus d side affects
Click on image below to visit fosamax Online Page
WEST POINT, Pa.–(BUSINESS WIRE)–Oct. 2, 1995–Merck & Co. Inc. Monday announced that the U.S. Food and Drug Administration has cleared for marketing Fosamax (alendronate sodium) to treat osteoporosis in women after menopause.
Fosamax, a breakthrough prescription medicine, builds healthy bone, restoring some of the bone lost as a result of osteoporosis. Fosamax is a new treatment choice and the first nonhormonal medicine for women after menopause who have this bone-weakening disease, which leads to osteoporotic fractures in more than one in three women over age 50.
“Until recently, the only treatments for osteoporosis, a potentially painful, disabling and sometimes life-threatening disease, were hormonal. Finally, there is a new treatment choice women can discuss with their physicians,” said Ethel Siris, Actonel vs fosamax
Colorado fosamax attorneys
Rls treatment fosamax
Fosamax vs evista
Fosamax and inner ear bones
colorado fosamax attorneys
Fosamax jaw